



Innovations in Neonatal Care: The Future is Now

Topic: The field of Neonatology is constantly evolving with new evidence and treatment options to improve the care of our most fragile patients. World renown speakers will be addressing some of the current advances and studies in neonatal medicine, to include management of the peri-viable infant, current management of pulmonary arterial hypertension, the use of low dose hydrocortisone, a current look into BPD, timing of inguinal hernia repair, effects of sedation, narcotics on the development of an infant, possible neuro-protective role of erythropoietin, point of care ultrasound, optimizing the nutritional aspect of our extreme premature infant and the current evidence for probiotics. A round table with an expert panel will discuss the use of postnatal steroids. As a participant in this educational activity, you will also be able to appreciate the complex ethical, quality and safety issues inherent in taking care of vulnerable newborn infants.

Date: 8/11/2019 – 8/13/2019

Location: Austin , TX

Accreditations:

The MEDNAX Center for Research, Education, Quality and Safety is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The MEDNAX Center for Research, Education, Quality and Safety designates this Live Activity for a maximum of 17.00 *AMA PRA Category 1 Credits™*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

The MEDNAX Center for Research, Education, Quality and Safety designates this Live Activity for a maximum of 0.75 credit(s) in Ethics.

The MEDNAX Center for Research, Education, Quality and Safety is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. (#PO258)

The MEDNAX Center for Research, Education, Quality and Safety designates this Live Activity for a maximum of 17.00 nursing contact hour(s). Participants should only claim credit commensurate with the extent of their participation in the activity.

The MEDNAX Center for Research, Education, Quality and Safety designates this live activity for a maximum of 2.75 *pharmacotherapeutics contact hours*, and a maximum of .75 *ethics contact hours*.

Presentations with Pharmacotherapeutics Contact Hours	
<i>Presentations</i>	<i>Contact Hour(s)</i>
<i>Current Management of Pulmonary Arterial Hypertension in the BPD Infant</i>	0.25
<i>Update on the Use of Postnatal Steroids in the NICU</i>	0.25
<i>Roundtable Discussion Topic: The Use of Postnatal Steroids</i>	.75
<i>The Effects of Analgesics & Sedatives on Neonatal Outcomes</i>	.75
<i>Is Erythropoietin Neuroprotective?</i>	.75

Disclosure of Financial Relationships:

Disclosure of Financial Relationships and Resolution of Conflicts of Interest is designed to ensure quality, objective, balanced, and scientifically rigorous continuing education activities. All individuals in a position to influence and/or control the content of continuing education activities have been asked to disclose all relevant financial relationships within the past 12 months. Any real or apparent conflicts of interest related to the content of the faculty's presentation have been resolved as have any real or apparent conflicts of interest by the planners as related to the content of this conference. Beyond disclosure of relevant financial relationships, faculty are required to disclose when they plan to discuss pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical. The MEDNAX Center for Research, Education, Quality and Safety is committed to providing learners with commercially unbiased continuing education activities.

The faculty, moderators and planners of this activity have the following financial relationship(s) with commercial interests to disclose:

Steven Abman, MD Disclosure(s) - Consulting Fee - Takeda Pharmaceuticals, Inc.; Contracted Research - Takeda Pharmaceuticals, Inc. and Actelion; Educational Grant - Mallinckrodt, Inc.; Research Funding - Shire Pharmaceuticals; United Therapeutics; Scientific Advisor - GlaxoSmithKline and Chiesi

Tim Biela, MD Disclosure(s) - I/we have no financial relationships to report.

Robert Christensen, MD Disclosure(s) - I/we have no financial relationships to report.

Reese H Clark, MD Disclosure(s) - I/we have no financial relationships to report. Postnatal Steroids – investigational use is discussed.

Yasser Elsayed, MD, PhD Disclosure(s) - I/we have no financial relationships to report.

Úrsula Guillén, MD Disclosure(s) - I/we have no financial relationships to report. Part of this work was supported by an Institutional Development Award (IDeA) from NIH grant U54-GM104941 and by The Gerber Foundation.

Matthew Harting, MD Disclosure(s) - I/we have no financial relationships to report.

Alan Jobe, MD Disclosure(s) - Chiesi - research grant to study budesonide + surfactant in sheep models on Australia-Chiesi Pharm, Consulting Fee - Chiesi - consult for BPD, Research on Antenatal steroids - grant-GlaxoSmithKline - Steroid Pharmacokinetics, donate supplies for ventilation of sheep-Fisher and Paykel – NZ; B&M Gates Foundation – Grant – Antenatal steroid studies & Consulting - Infant mortality in low resource environments; Merck – Research Gift- Betamethasone; Off-label drugs used in treating BPD in infants

Camilia Martin, MD Disclosure(s) - Contracted Research - Alcresta Therapeutics & Abbott Laboratories, Consulting Fee - Mead Johnson Nutrition; Scientific Advisory Board-Fresenius Kabi & Prolacta Biosciences

Christopher McPherson, PharmD Disclosure(s) - I/we have no financial relationships to report. Unapproved/Off-label use of drugs will be discussed.

Robin Ohls, MD Disclosure(s) - I/we have no financial relationships to report. Non-approved use of Erythropoiesis Stimulating Agents (ESAs) Erythropoietin (Epo) and Darbepoetin (Darbe) will be discussed.

Betsy Ostrander, MD Disclosure(s) - I/we have no financial relationships to report.

Ravi Patel, MD, MSc Disclosure(s) - Travel support to attend SIGNEC 2018 conference (UK)-Danone Nutricia Probiotics are not FDA approved for the prevention of any neonatal diseases.

Jochen Profit, MD, MPH Disclosure(s) - I/we have no financial relationships to report. RCT of WISER program to reduce caregiver burnout - NICHD R01 - HD084679 (Co-PI, Bryan Sexton); Collaboration on POKE project - Stanford Intermountain Grant (Co-PI, Erick Ridout); Chief Quality Officer of CPQCC

Danielle Rios, MD Disclosure(s) - I/we have no financial relationships to report.

Rashmin Savani, MD Disclosure(s) - Speakers Bureau - Abbott Laboratories; Ownership Interest - Eravon Therapeutics, Inc.; Consulting Fee - Mallinckrodt, Inc.

Gautham Suresh, MD, DM, MS Disclosure(s) - I/we have no financial relationships to report.

Jonathan Swanson, MD, MSc Disclosure(s) - Speakers Honorarium - Prolacta Biosciences, Inc.

John Zupancic, MD Disclosure(s) - I/we have no financial relationships to report.

Talat Ahmed, MD Disclosure(s) - I/we have no financial relationships to report.

Frank Cho, MD Disclosure(s) - I/we have no financial relationships to report.

Hilja Dodd Sousa Conceicao, CHCP, CPHQ Disclosure(s) - I/we have no financial relationships to report.

Kassandra S Greci, DNP, APRN, WHNP-BC Disclosure(s) - I/we have no financial relationships to report.

Stephanie A Mahan, NNP Disclosure(s) - I/we have no financial relationships to report.
Kimberly Maurel, RN, MSN, CNS Disclosure(s) - I/we have no financial relationships to report.
Cheryl Motta, MD Disclosure(s) - I/we have no financial relationships to report.
Vijay Nama, MD Disclosure(s) - I/we have no financial relationships to report.
David Riley, MD Disclosure(s) - I/we have no financial relationships to report.
Vivek Vijayamadhavan, MD Disclosure(s) - I/we have no financial relationships to report.
David Weisoly, DO Disclosure(s) - I/we have no financial relationships to report.
Patti Wendorf, APRN Disclosure(s) - I/we have no financial relationships to report.

Operations Management - Individuals are not involved in content planning.

Nicole Brenson, MEd – Operations Manager, Clinical Services Division & The MEDNAX CREQS

Cindy Chiapetta – Continuing Education Program Coordinator, The MEDNAX CREQS

Janet Samuel – Meeting Planner, The MEDNAX CREQS

Commercial Support:

This meeting is supported in part, through restricted medical education grants from Abbott Nutrition and Mallinckrodt LLC.

The MEDNAX Center for Research, Education, Quality and Safety thanks those companies participating in the commercial support of its educational activities. However, our appreciation does not imply that MEDNAX endorses or encourages the use of products manufactured or services provided by participating companies.

Purpose

The purpose of this educational activity is to enhance clinician knowledge in the evolving area of Neonatology with new evidence and treatment options to improve the care of our most fragile patients. This educational activity was designed for participants to better understand and utilize the leading approaches to neonatal intensive care addressed in the sessions.

Learning Outcome

The participant will appropriately implement at least one (or more) new strategy, technique(s) or intervention(s) to improve neonatal patient care and outcomes.

Competencies

CME – ABMS/ACGME Competencies addressed in this activity include Patient Care, Medical Knowledge Interpersonal and communication skills, and Professionalism.

Objectives: At the conclusion of this activity, the participant should be able to:

ACCME Objectives

1. Summarize short and long-term outcomes for the periviable infant
2. Assess treatment and strategies to improve the outcome of extreme premature infants.
3. Develop ways to better counsel families of the extremely preterm infant prior to delivery.
4. Define the new platelet transfusion criteria as it relates to patients in the NICU.
5. Discuss mortality rates of the extremely low birth weight infant.
6. Describe the current medical management of pulmonary hypertension in the infant with BPD.
7. Identify the risks/benefits of the use of postnatal steroids in the NICU.
8. Analyze the various methods of using postnatal steroids.
9. Use The Choosing Wisely Top Five for quality improvement efforts to optimize clinical outcomes and resource utilization in newborn care.
10. Discuss preventative strategies and how they relate to the pathophysiology of NEC.
11. Compare current strategies in the management of congenital diaphragmatic hernia.
12. Identify Erythropoietin as a means for neuroprotection.
13. Describe early signs and symptoms of cerebral palsy.
14. Recognize the value of Point of Care ultrasound in the NICU.

15. Compare differences and similarities between mother's own milk and donor milk.
16. Discuss the latest evidence on the use of intralipids in the NICU.
17. Examine the use of probiotics and the benefits for the NICU patient.
18. Identify developmental risks of sedation, narcotics, and anesthesia in the neonate.

ANCC Learning Outcomes

1. Discuss treatment and strategies to improve the outcome of extreme premature infant.
2. Understand the effects of sedation, narcotics and anesthesia on the developmental of the neonate.
3. Discuss a model of NEC and potential treatment.
4. Identify the role of bedside echocardiography and point-of-care ultrasound.
5. Discuss ways to optimize nutrition in the extremely premature infant.

Evaluation, Attendance and Credit:

Within <https://mednax.cloud-cme.com>, click My CE and then select Evaluations and Certificates. Follow the instructions to record attendance/time spent and complete the brief evaluation. You will have the option to email the certificate of attendance to your mailbox.